Pediatric HIV Infection
8
2
2
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 8 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (8)
Dolutegravir Pharmacokinetics Among HIV/TB Coinfected Children Receiving Standard and High-dose Rifampicin
Dolutegravir Pharmacokinetics During Weekly Rifapentine/Isoniazid for TB Prevention
Pharmacokinetics, Safety, and Efficacy of Dolutegravir Dispersible Tablets in Young Children Living With HIV
Evaluating the Feasibility of Point of Care Birth Testing in Eswatini
Impact of Point-of-Care EID for HIV-Exposed Infants
Evaluating an HIV Risk Screening Tool for Orphans and Vulnerable Children in Tanzania
Utilizing the HITSystem for Optimizing Paediatric ART Retention and Adherence in Western Nyanza Province, Kenya
Active Search for Pediatric HIV/AIDS (ASPA)